Original Article
Occult Hepatitis B Virus Infection in Patients with Chronic Hepatitis C Liver Disease
N Engl J Med 1999; 341:22-26July 1, 1999
- Abstract
Background
Hepatitis B virus (HBV) infections in patients who lack detectable hepatitis B surface antigen (HBsAg) are called occult infections. Although such infections have been identified in patients with chronic hepatitis C liver disease, their prevalence and clinical significance are not known.
Methods
With the polymerase chain reaction, we searched for HBV DNA in liver and serum samples from 200 HBsAg-negative patients with hepatitis C virus (HCV)–related liver disease (147 with chronic hepatitis, 48 with cirrhosis, and 5 with minimal histologic changes). One hundred of the patients had detectable antibodies to the HBV core antigen (anti-HBc); 100 were negative for all HBV markers. Eighty-three were treated with interferon alfa. We also studied 50 patients with liver disease who were negative both for HBsAg and for HCV markers. In six patients found to have occult HBV infection, we evaluated possible genomic rearrangements through cloning or direct sequencing procedures.
Results
Sixty-six of the 200 patients with chronic hepatitis C liver disease (33 percent) had HBV sequences, as did 7 of the 50 patients with liver disease unrelated to hepatitis C (14 percent, P=0.01). Among the 66 patients, 46 were anti-HBc–positive and 20 were negative for all HBV markers (P<0.001). Twenty-two of these 66 patients (33 percent) had cirrhosis, as compared with 26 of the 134 patients with hepatitis C infection but no HBV sequences (19 percent, P=0.04). HBV sequences were detected in 26 of the 55 patients in whom interferon therapy was ineffective and 7 of the 28 patients in whom interferon therapy was effective (P=0.06). None of the sequenced HBV genomes had changes known to interfere with viral activity and gene expression.
Conclusions
Occult hepatitis B infection occurs frequently in patients with chronic hepatitis C liver disease and may have clinical significance.
Media in This Article
Table 1
Base-Line Characteristics of the Patients.Table 2
Prevalence of Occult HBV Infection in Patients with and without Chronic HCV Infection and with and without Antibodies to the HBV Core Antigen (Anti-HBc).Article Activity
- Article
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for a substantial proportion of liver disease worldwide. HCV is an RNA virus of the Flaviviridae family. HBV is a DNA virus of the Hepadnaviridae family. It contains four open reading frames: the S gene, coding for the envelope proteins; the core gene, coding for the core and “e” proteins; the P gene, coding for a DNA polymerase; and the X gene, coding for a transcriptional transactivator. HBV and HCV are both transmitted through the blood and by sexual contact. Infection with both viruses is frequent, particularly in areas where the two viruses are endemic and among people at high risk for parenteral infections.1-5 HCV infection is diagnosed by the detection of specific antibodies and viral RNA in the serum. HBV infection is usually diagnosed when circulating hepatitis B surface antigen (HBsAg) is identified.
Many studies have shown that HBV infection may occur in HBsAg-negative patients with or without serologic markers of previous infection (antibodies to HBsAg [anti-HBs] or to the hepatitis B core antigen [anti-HBc]).6-8 The reasons for the lack of circulating HBsAg in such patients are unknown. Recent observations have suggested that the lack of HBsAg may be due to rearrangements in the HBV genome that interfere with gene expression or lead to the production of an antigenically modified S protein.9-11 Occult HBV infection has frequently been identified in patients with HCV-related chronic hepatitis. Considerable data suggest that this occult infection may contribute to chronic liver damage and the development of hepatocellular carcinoma.12-17 Despite its potential clinical importance, the prevalence of occult HBV infection in patients with hepatitis C is still undetermined.
We analyzed the prevalence of occult HBV infection in patients with chronic hepatitis C. Our goals were to determine whether the failure to detect HBsAg is related to viral genomic variability and to evaluate the possible relation between occult HBV infection and the clinical outcome of the liver disease.
Methods
Patients
Between January 1991 and June 1997 at our institution, percutaneous needle biopsy of the liver was performed in 396 patients who had HCV-related chronic liver disease, had no detectable HBsAg, did not drink alcohol to excess or use intravenous drugs, and were not infected with the human immunodeficiency virus. HCV infection was defined by the presence of anti-HCV antibodies and HCV RNA in serum.18 One hundred forty of these patients had serum markers of previous HBV infection; all were anti-HBc–positive, and 112 were also anti-HBs–positive. The remaining 256 were negative for all HBV markers.
During the same period, 50 patients with liver disease and no detectable HBsAg or HCV markers underwent liver biopsy (Table 1Table 1
Base-Line Characteristics of the Patients.). Part of each liver specimen was processed for histologic and possible immunohistochemical examination; the rest was immediately frozen and stored at –80°C for subsequent molecular analyses. Serum samples were collected from each patient and frozen for further studies.We analyzed specimens from 200 HCV-infected patients (the HCV-positive group) and all 50 patients who were negative for HBsAg and HCV markers (the HCV-negative group) (Table 1). The HCV-positive group consisted of consecutively admitted patients, 100 of whom were anti-HBc–positive (the HCV-positive and anti-HBc–positive subgroup) and 100 of whom were negative for HBV markers (the HCV-positive and anti-HBc–negative subgroup). According to the histologic findings, the patients were divided into three categories: those with minimal or nonspecific changes, those with mild-to-moderate chronic hepatitis, and those with severe chronic hepatitis with features of cirrhosis.
Three HCV-positive and anti-HBc–positive patients had a documented history of self-limited acute hepatitis B (one patient) or chronic hepatitis B (two patients). The liver specimens we analyzed were obtained from these patients five, four, and eight years, respectively, after the clearance of serum HBsAg. Retrospective analysis of their stored serum samples showed detectable anti-HCV antibodies from the beginning of the follow-up.
None of the patients we studied had been treated with antiviral or immunosuppressive drugs before undergoing liver biopsy. Subsequently, 83 patients with HCV infection (65 with chronic hepatitis and 18 with cirrhosis; 28 from the HCV-positive and anti-HBc–positive subgroup and 55 from the HCV-positive and anti-HBc–negative subgroup) were treated with 3 million to 6 million units of interferon alfa three times a week for four to six months, and if the results of liver-function tests became normal, with 3 million units three times a week for another six to eight months. In 28 of these patients (7 who were anti-HBc–positive and 21 who were anti-HBc–negative), the therapy was considered successful, since they had normal results on tests of liver function and had no detectable HCV RNA for at least six months after stopping therapy.
The study protocol was approved by the ethics committee of the University of Messina, and all the patients provided written informed consent.
HBV DNA Analyses
DNA was extracted from the frozen liver specimen of each patient by standard procedures.19 All liver DNA extracts were analyzed for HBV genomes with two different polymerase chain reaction (PCR) assays to detect the S and core genes, according to previously described methods.20 Briefly, 100 μl of reaction mixture containing 10 μl of extracted DNA, 50 mM potassium chloride, 10 mM TRIS–hydrochloric acid (pH 8.3), 2 mM magnesium chloride, 200 μM deoxyribonucleosides, 2.5 U of Taq polymerase (Perkin–Elmer Cetus, Norwalk, Conn.), and 20 pmol each of the oligonucleotide primers HBV1 and HBV2 for the S gene and primers HBV3 and HBV4 for the core gene was overlaid with 100 μl of mineral oil. Amplification was performed for 35 cycles, each consisting of denaturing for 30 seconds at 94°C, annealing for 45 seconds at 56°C, and extension for 1.5 minutes at 72°C. The amplification products were visualized on an ethidium bromide–stained 1 percent agarose gel. When no amplification product was seen on the gel, a second round of nested PCR amplification was performed with 10 μl from the product of the first reaction and the inner primers HBV5 and HBV6 for the S region and HBV7 and HBV8 for the core region.21
The patients who were found positive for only one of the two regions examined were retested by single-step or nested PCR procedures with the use of sets of oligonucleotide primers (HBV9 and HBV10, and HBV11 and HBV12) encompassing the viral X gene. They were considered to be definitely infected or uninfected with HBV according to the results of this additional test. The primers used were complementary to conserved regions of HBV genotype D at the following positions (from 5' to 3'): HBV1, 61–81; HBV2, 1004–985; HBV3, 1778–1800; HBV4, 2483–2464; HBV5, 154–174; HBV6, 839–819; HBV7, 1928–1946; HBV8, 2391–2372; HBV9, 968–986; HBV10, 1951–1931; HBV11, 1266–1283; and HBV12, 1804–1784. The limits of sensitivity of our single-step and nested PCR methods were 1×10–3 pg and 1×10–6 pg of cloned HBV DNA, respectively. Direct sequencing of randomly chosen amplification products showed different sequences between patients, which confirmed the specificity of the reactions.20
DNA was also extracted from serum samples from all the patients with intrahepatic HBV genomes and from 35 additional patients randomly selected from among those who were negative for intrahepatic viral DNA. The entire S gene of HBV isolated from three patients with occult infection who were randomly chosen from the HCV-positive group was amplified with the use of two hybrid oligonucleotide primers, cloned into a pUC19 vector, and sequenced by previously described procedures.22,23 Further studies in these patients included direct sequencing of the entire core gene of HBV isolates and testing for HBsAg and hepatitis B core antigen (HBcAg) in liver sections by immunohistochemical methods.19 The three patients who had been HBsAg-positive five to eight years before this study had occult HBV infection. The entire HBV genome from two of these patients was amplified and sequenced.24 In the other, the amount of DNA was just sufficient for analysis of the entire S, core, and X viral genes. Liver sections from these three patients were also tested for HBsAg and HBcAg.
The HBV sequences we obtained were aligned and compared with those in the National Center for Biotechnology Information data bank.
HCV RNA Genotyping and Quantification
The HCV genotype was determined in 62 of the 83 subjects treated with interferon alfa and in 38 additional patients randomly selected from those with or without occult HBV infection (HCV Genotyping, Sorin–Biomedica, Saluggia, Italy). We also evaluated the levels of HCV virus in nine randomly chosen patients with occult HBV infection and nine without occult HBV infection (Amplicor-HCV-Monitor, Roche, Basel, Switzerland).
Statistical Analysis
Student's t-test and the Mann–Whitney test were used to analyze quantitative data. Fisher's exact test was used to analyze qualitative data and for comparing proportions.25,26 All P values are two-tailed; a P value <0.05 was considered to indicate statistical significance.
Results
Intrahepatic HBV sequences were detected in 73 of the 250 specimens examined. In 64 patients both core and S genes were detected, whereas in 9 patients the X gene besides the S (4 patients) or core (5 patients) region was amplified. HBV genomes were found in the serum of 45 of the 73 patients with intrahepatic HBV and in none of the 35 patients without intrahepatic HBV. Liver HBV DNA was detected after single-step PCR amplification in 35 patients and after nested PCR in 38 patients. Serum HBV DNA was found in all patients by nested PCR. HBV sequences were found in liver tissue from 66 of the 200 HCV-infected patients (33 percent) and in 7 of the 50 HCV-negative patients (14 percent, P=0.01) (Table 2Table 2
Prevalence of Occult HBV Infection in Patients with and without Chronic HCV Infection and with and without Antibodies to the HBV Core Antigen (Anti-HBc).). Forty-six patients in the subgroup that was HCV-positive and anti-HBc–positive and 20 of those in the subgroup that was HCV-positive and anti-HBc–negative were HBV-positive (P<0.001) (Table 2). Six of the seven HCV-negative patients with occult HBV infection had cryptogenic liver disease, and one had hemochromatosis. The prevalence of occult HBV infection among HCV-infected patients did not differ with sex or age, except that among patients with cirrhosis, those with HBV tended to be younger than those without HBV (51±10 vs. 56±7 years, P=0.06). The prevalence of the different HCV genotypes was similar in patients with and those without occult HBV infection (Table 3Table 3
Characteristics of the Patients with Chronic HCV Infection, According to the Presence or Absence of Occult HBV Infection.). Quantification of serum HCV RNA showed very similar viral levels in patients with occult infection and those without such infection (Table 3).Twenty-two of the 66 patients with HCV infection and occult HBV infection (33 percent) had cirrhosis, as compared with 26 of the 134 patients with HCV infection and no occult HBV infection (19 percent, P=0.04) (Table 3). There was no significant association between occult HBV infection and chronic hepatitis (P=0.13). HBV sequences were detected in 26 of 55 patients in whom interferon therapy was unsuccessful and in 7 of 28 patients in whom the therapy was successful (P=0.06) (Table 4Table 4
Response to Interferon Treatment in Patients with Chronic HCV Liver Disease with or without Occult HBV Infection.). By separately evaluating the 65 patients with chronic hepatitis and the 18 with cirrhosis, we found a trend toward an association between occult HBV infection and a lack of response to interferon therapy in the patients with chronic hepatitis (P=0.07) but not in those with cirrhosis (Table 4). The relation of occult HBV infection to both cirrhosis and a lack of response to interferon therapy was not significantly affected by sex (P=0.8 and P=0.4, respectively), age (P=0.06 and P=0.7, respectively), or infecting HCV genotype (P=0.7 and P=0.6, respectively).The entire S gene of the HBV isolated from three patients with occult infection was amplified and cloned. The nucleotide-sequence analysis of five clones for each patient showed that the viral populations infecting each were genetically almost identical and were homologous with published genotype D prototypes. Consequently, we did not detect changes capable of preventing the synthesis or modifying the antigenic structure of HBsAg. Similarly, the direct sequencing of the core gene of HBV from these three patients showed very few irrelevant mutations in each (data not shown). HBsAg and HBcAg were not detected in liver tissue.
We considered it essential to sequence the entire HBV genome in order to verify whether specific mutations were associated with occult infection.27 We extensively analyzed HBV genomes from three subjects with documented histories of acute or chronic hepatitis B. The sequencing analyses showed that two of them were infected by genotype D1 and one by genotype D5. No genomic changes known to be able to interfere with viral activity were detected. No HBsAg or HBcAg was immunohistochemically detected in their liver-biopsy specimens.
Discussion
We investigated HBV infection in HBsAg-negative patients with chronic hepatitis C. We found that one third of the patients with HCV-related chronic hepatitis had detectable HBV genomes, despite the absence of circulating HBsAg. This prevalence was significantly higher than that among HCV-negative patients with chronic liver disease. The prevalence of occult HBV infection was particularly high among patients with anti-HBV antibodies. Occult HBV infection was also detected in patients who were negative for all HBV serum markers. The reasons for the disappearance of HBsAg and, in some cases, of all HBV markers despite the persistence of HBV infection are not known. Recent reports suggest that rearrangements of the viral genome, particularly in the S gene, may be responsible for the failure to detect HBsAg.9-11 We cloned and sequenced the S region of three isolates and directly sequenced the entire genome from three more patients; no mutation known to be capable of interfering with viral activity or gene expression was detected. These findings support the view that variability of the virus is not a major reason that HBV infection can be occult.
In agreement with most reports,6-9,12,16,27 we found very low levels of viremia in patients with occult HBV infection. Serum HBV DNA was detected with the very sensitive nested PCR technique in just 45 of the 73 subjects with intrahepatic viral genomes. Immunoperoxidase staining for HBV surface and core proteins was negative in all the liver-biopsy specimens examined, although molecular analyses showed that the corresponding viral genes in these specimens were normal. Together, these data suggest that occult HBV infection is usually due to a strong suppression of viral replication and gene expression. The mechanisms responsible for the inhibition of HBV activity are undefined. Much evidence suggests that the immune system may have a key role.28-33 In patients with HCV coinfection, it is also possible that this virus may suppress HBV activity.2,3,34-36
HBV particles may persist for decades after self-limited acute hepatitis and clinical recovery.28,37,38 Thus, occult infection alone may not have clinical consequences and may become injurious only when the virus is reactivated after immunosuppression.29-33 Nevertheless, HBV genomes have also been found in patients with idiopathic liver disease.12,17 In our study six of the seven patients without HBsAg or markers of HCV and with occult HBV had a diagnosis of cryptogenic chronic hepatitis or cirrhosis. Such evidence might lead to speculation about a possible pathogenic role of HBV in liver injury, despite the suppression of its activity. However, other yet-to-be-identified factors (including unknown viruses) may be the main cause of liver damage in such patients.
Many epidemiologic and molecular studies indicate that persistent HBV infection may have a critical role in the development of hepatocellular carcinoma in HBsAg-negative patients.13-15,17,39-41 This hypothesis is supported by studies showing that both woodchucks and ground squirrels that have once been infected by woodchuck hepatitis virus and ground-squirrel hepatitis virus, respectively, are at high risk for hepatocellular carcinoma even after the apparent clearance of the virus.42,43 Occult HBV and its potential oncogenicity are traditionally considered a consequence of the capacity of the virus to be integrated into the host genome, although many observations show that free episomal HBV genomes may persist in the liver cells during occult infection.7,8
Our study demonstrates that occult HBV infection is significantly correlated with cirrhosis among HCV-infected patients. This suggests that a masked HBV infection may interfere with the clinical outcome of chronic hepatitis C and favor or accelerate the evolution to cirrhosis. Cirrhosis is generally considered the most important risk factor for the development of hepatocellular carcinoma. Thus, in addition to its possible direct oncogenic properties, occult HBV infection may favor neoplastic transformation in HCV-infected patients through its contribution to cirrhosis.
A recent study showed that in HCV-infected patients with chronic active hepatitis and Child's class A cirrhosis, interferon therapy, as compared with no treatment, reduced the risk of hepatocellular carcinoma by a factor of more than six only in patients who were negative for all serum HBV markers.44 Our results, by suggesting that occult HBV infection correlates with a lack of response to interferon treatment in patients with chronic hepatitis C, are in agreement with these findings44 and with previous data obtained in a study of 14 patients.45
Supported in part by a grant from the Ministero dell'Università e Ricerca Scientifica e Tecnologica of Italy.
We are indebted to Pierfrancesco Cacciola, M.Sc., who performed the statistical analyses.
Source Information
From the Dipartimento di Medicina Interna, Università di Messina, Messina, Italy.
Address reprint requests to Dr. Raimondo at the Dipartimento di Medicina Interna, Policlinico Universitario, 98100 Messina, Italy, or at raimondo@imeuniv.unime.it.
- References
References
1
Fattovich G ,Tagger A ,Brollo L , et al. Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis 1991;163:400-402
CrossRef | Web of Science | Medline2
Sato S ,Fujiyama S ,Tanaka M , et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 1994;21:159-166
CrossRef | Web of Science | Medline3
Crespo J ,Lozano JL ,de la Cruz F , et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol 1994;89:1147-1151
Web of Science | Medline4
Alberti A ,Pontisso P ,Chemello L , et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol 1995;22:Suppl:38-41
Web of Science | Medline5
Zarski J-P ,Bohn B ,Bastie A , et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33
CrossRef | Web of Science | Medline6
Thiers V ,Nakajima E ,Kremsdorf D , et al. A transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet 1988;2:1273-1276
CrossRef | Web of Science | Medline7
Liang TJ ,Blum HE ,Wands JR . Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers. Hepatology 1990;12:204-212
CrossRef | Web of Science | Medline8
Zhang Y-Y ,Hansson BG ,Kuo LS ,Widell A ,Nordenfelt E . Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology 1993;17:538-544
CrossRef | Web of Science | Medline9
Blum HE ,Galun E ,Liang TJ ,von Weizsacker F ,Wands JR . Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol 1991;65:1836-1842
Web of Science | Medline10
Yamamoto K ,Horikita M ,Tsuda F , et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994;68:2671-2676
Web of Science | Medline11
Carman WF ,Van Deursen FJ ,Mimms LT , et al. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia. Hepatology 1997;26:1658-1666
CrossRef | Web of Science | Medline12
Liang TJ ,Baruch Y ,Ben-Porath E , et al. Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology 1991;13:1044-1051
CrossRef | Web of Science | Medline13
Sheu JC ,Huang GT ,Shih LN , et al. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992;103:1322-1327
Web of Science | Medline14
Paterlini P ,Driss F ,Nalpas B , et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology 1993;17:20-29
CrossRef | Web of Science | Medline15
Paterlini P ,Poussin K ,Kew M ,Franco D ,Brechot C . Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995;21:313-321
CrossRef | Web of Science | Medline16
Koike K ,Kobayashi M ,Gondo M ,Hayashi I ,Osuga T ,Takada S . Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998;54:249-255
CrossRef | Web of Science | Medline17
Huo TI ,Wu JC ,Lee PC , et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998;28:231-236
CrossRef | Web of Science | Medline18
Feray C ,Samuel D ,Thiers V , et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992;89:1361-1365
CrossRef | Web of Science | Medline19
Villari D ,Raimondo G ,Smedile V , et al. Hepatitis B-DNA replication and histological patterns in liver biopsy specimens of chronic HBsAg positive patients with and without hepatitis delta virus superinfection. J Clin Pathol 1989;42:689-693
CrossRef | Web of Science | Medline20
Pollicino T ,Campo S ,Raimondo G . PreS and core gene heterogeneity in hepatitis B virus (HBV) genomes isolated from patients with long-lasting HBV chronic infection. Virology 1995;308:672-677
CrossRef | Web of Science21
Schepis F ,Verucchi G ,Pollicino T , et al. Outcome of liver disease and response to interferon treatment are not influenced by hepatitis B virus core gene variability in children with chronic type B hepatitis. J Hepatol 1997;26:765-770
CrossRef | Web of Science | Medline22
Grotzinger T ,Will H . Sensitive method for identification of minor hepatitis B mutant viruses. Virology 1992;187:383-387
CrossRef | Web of Science | Medline23
Pollicino T ,Zanetti AR ,Cacciola I , et al. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology 1997;26:495-499
CrossRef | Web of Science | Medline24
Pollicino T ,Pernice F ,Campo S , et al. Severe outcome of hepatitis B virus (HBV) infection and lack of HBV e antigen-defective virus emergence in patients homozygous for HLA class I alleles. J Gen Virol 1996;77:1833-1836
CrossRef | Web of Science | Medline25
Siegel S, Castellan NJ Jr. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill, 1998.
26
Armitage P, Berry G. Statistical methods in medical research. 3rd ed. London: Blackwell Scientific, 1994.
27
Chazouilleres O ,Mamish D ,Kim M , et al. “Occult“ hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343:142-146
CrossRef | Web of Science | Medline28
Penna A ,Artini M ,Cavalli A , et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996;98:1185-1194
CrossRef | Web of Science | Medline29
Hoofnagle JH ,Dusheiko GM ,Schafer DF , et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447-449
Web of Science | Medline30
Waite J ,Gilson RJC ,Weller IVD , et al. Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS 1988;2:443-448
CrossRef | Web of Science | Medline31
Grumayer ER ,Panzer S ,Ferenci P ,Gadner H . Recurrence of hepatitis B in children with serologic evidence of past hepatitis B virus infection undergoing antileukemic chemotherapy. J Hepatol 1989;8:232-235
CrossRef | Web of Science | Medline32
Lok ASF ,Liang RHS ,Chiu EKW ,Wong KL ,Chan TK ,Todd D . Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991;100:182-188
Web of Science | Medline33
Marcellin P ,Giostra E ,Martinot-Peignoux M , et al. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 1991;100:1432-1434
Web of Science | Medline34
Sheen IS ,Liaw YF ,Chu CM ,Pao CC . Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis 1992;165:831-834
CrossRef | Web of Science | Medline35
Villa E ,Grottola A ,Trande T , et al. Reactivation of hepatitis B virus infection induced by interferon (INF) in HBsAg-positive, antiHCV-positive patients. Lancet 1993;341:1413-1413
CrossRef | Web of Science | Medline36
Shih CM ,Lo SJ ,Miyamura T ,Chen SY ,Lee YH . Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993;67:5823-5832
Web of Science | Medline37
Michalak TI ,Pasquinelli C ,Guilhot S ,Chisari FV . Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994;93:230-239[Erratum, J Clin Invest 1994;94:905a.]
CrossRef | Web of Science | Medline38
Yotsuyanagi H ,Yasuda K ,Iino S , et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998;27:1377-1382
CrossRef | Web of Science | Medline39
Shafritz DA ,Shouval D ,Sherman HI ,Hadziyannis SJ ,Kew MC . Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. N Engl J Med 1981;305:1067-1073
Full Text | Web of Science | Medline40
Brechot C ,Hadchouel M ,Scotto J , et al. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci U S A 1981;78:3906-3910
CrossRef | Web of Science | Medline41
Paterlini P ,Gerken G ,Nakajima E , et al. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med 1990;323:80-85
Full Text | Web of Science | Medline42
Korba BE ,Wells FV ,Baldwin B , et al. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology 1989;9:461-470
CrossRef | Web of Science | Medline43
Marion PL. Ground squirrel hepatitis virus. In: McLachlan A, ed. Molecular biology of hepatitis B virus. Boca Raton, Fla.: CRC Press, 1991:39-51.
44
International Interferon-(alpha) Hepatocellular Carcinoma Study Group
CrossRef | Web of Science | Medline45
Zignego AL ,Fontana R ,Puliti S , et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997;51:313-318
CrossRef | Web of Science | Medline
- Citing Articles (226)
Citing Articles
1
Jama M. Darling, Stanley M. Lemon, Michael W. Fried. 2011. Hepatitis C. , 582-652.
CrossRef2
Kalyan Ram Bhamidimarri, James Park, Douglas Dieterich. (2011) Management of Hepatitis B Virus Coinfection: HIV, Hepatitis C Virus, Hepatitis D Virus. Current Hepatitis Reports 10:4, 262-268
CrossRef3
Anna S. Lok, James E. Everhart, Adrian M. Di Bisceglie, Hae-Young Kim, Munira Hussain, Timothy R. Morgan, . (2011) Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 54:2, 434-442
CrossRef4
M. Nemayandeh, R. Yaghobi, B. Geramizadeh, M. Ayatollahi, S.A. Malek-Hosseini, S. Nikeghbalian, H. Salahi, A. Bahador, M.H. Karimi. (2011) Hematologic and Biochemical Indices and Viral Hepatitis in Liver Transplant Patients. Transplantation Proceedings 43:2, 612-614
CrossRef5
K. Arjmandi, R. Yaghobi, M. Ravanshad, S.Y. Hosseini, J. Roozbeh, M. Pakfetrat. (2011) Laboratory Effect of HBV Infection in Kidney Transplant Recipients and Donors. Transplantation Proceedings 43:2, 554-556
CrossRef6
Y. Shi, Y. H. Wu, Wu Wei, W. J. Zhang, J. Yang, Z. Chen. (2011) Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Internationalno-no
CrossRef7
Lisa Y. Cho, Jae Jeong Yang, Kwang-Pil Ko, Boyoung Park, Aesun Shin, Min Kyung Lim, Jin-Kyoung Oh, Sohee Park, Yoon Jun Kim, Hai-Rim Shin, Keun-Young Yoo, Sue K. Park. (2011) Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: Systematic review and meta-analysis. International Journal of Cancer 128:1, 176-184
CrossRef8
Zeinab K Hassan, Mohamed M Hafez, Tarek M Mansor, Abdel Zekri. (2011) Occult HBV infection among Egyptian hepatocellular carcinoma patients. Virology Journal 8:1, 90
CrossRef9
Jae Young Jang, Soung Won Jeong, Sung Ran Cheon, Sae Hwan Lee, Sang Gyune Kim, Young Koog Cheon, Young Seok Kim, Young Deok Cho, Hong Soo Kim, So Young Jin, Yun Soo Kim, Boo Sung Kim. (2011) Clinical significance of occult hepatitis B virus infection in chronic hepatitis C patients. The Korean Journal of Hepatology 17:3, 206
CrossRef10
Yu Jin Kim, Jin Woo Lee, Yun Soo Kim, Sook-Hyang Jeong, Young Seok Kim, Hyung Joon Yim, Bo Hyun Kim, Chun Kyon Lee, Choong Kee Park, Sang Hoon Park. (2011) Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. The Korean Journal of Hepatology 17:3, 199
CrossRef11
Mohamed H Emara, Mohamed I Radwan. (2011) Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient. Virology Journal 8:1, 518
CrossRef12
Xiao Nan, Shuang Shi, Canqing Yu, Hui Zhuang. (2010) Meta-analysis of the association between anti-HBc seropositivity and a poor prognosis of chronic HCV infection. Hepatology Research 40:12, 1176-1187
CrossRef13
Paul Schmeltzer, Kenneth E. Sherman. (2010) Occult Hepatitis B: Clinical Implications and Treatment Decisions. Digestive Diseases and Sciences 55:12, 3328-3335
CrossRef14
Shailaja Jamma, Ghazi Hussain, Daryl T.-Y. Lau. (2010) Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony. Current Hepatitis Reports 9:4, 260-269
CrossRef15
S. Bagaglio, L. Porrino, A. Lazzarin, G. Morsica. (2010) Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption. Infection 38:5, 417-421
CrossRef16
Perumal Vivekanandan, Om Vir Singh. (2010) Molecular methods in the diagnosis and management of chronic hepatitis B. Expert Review of Molecular Diagnostics 10:7, 921-935
CrossRef17
Sonia Roman, Yasuhito Tanaka, Anis Khan, Fuat Kurbanov, Hideaki Kato, Masashi Mizokami, Arturo Panduro. (2010) Occult hepatitis B in the genotype H-infected Nahuas and Huichol native Mexican population. Journal of Medical Virology 82:9, 1527-1536
CrossRef18
Maria Stella De Mitri, Romina Cassini, Mauro Bernardi. (2010) Hepatitis B virus-related hepatocarcinogenesis: Molecular oncogenic potential of clear or occult infections. European Journal of Cancer 46:12, 2178-2186
CrossRef19
E. Seremba, P. Ocama, C.K. Opio, M. Kagimu, H.J. Yuan, N. Attar, D.L. Thomas, W.M. Lee. (2010) Validity of the rapid strip assay test for detecting HBsAg in patients admitted to hospital in Uganda. Journal of Medical Virology 82:8, 1334-1340
CrossRef20
C. Velati. (2010) Occult B hepatitis - still a risk for transfusions?. ISBT Science Series 5:n1, 73-76
CrossRef21
Akihiro Nasu, Hiroyuki Marusawa, Yoshihide Ueda, Yuji Eso, Makoto Umeda, Tsutomu Chiba, Yukio Osaki. (2010) De novo hepatitis B virus infection in hepatocellular carcinoma following eradication of hepatitis C virus by interferon therapy. Hepatology Research 40:6, 661-665
CrossRef22
Marion Levast, Sylvie Larrat, Marie-Ange Thelu, Sandrine Nicod, Agnès Plages, Alice Cheveau, Jean-Pierre Zarski, Jean-Marie Seigneurin, Patrice Morand, Vincent Leroy. (2010) Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin. Journal of Medical Virology 82:5, 747-754
CrossRef23
Shiou-Haur Liang, Tai-Jui Chen, Susan Shin-Jung Lee, Fan-Chen Tseng, Chun-Kai Huang, Chung-Hsu Lai, Chou-Ping Chiou, Jiun-Ling Wang, Hsing-Chun Chung, Jiun-Nong Lin, Yi-Chi Kuo, Hsi-Hsun Lin. (2010) Risk Factors of Isolated Antibody Against Core Antigen of Hepatitis B Virus: Association With HIV Infection and Age but not Hepatitis C Virus Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes1
CrossRef24
J. P. Hwang, M. Mohseni, B. J. Gor, S. Wen, H. Guerrero, J. M. Vierling. (2010) Hepatitis B and Hepatitis C Prevalence and Treatment Referral Among Asian Americans Undergoing Community-Based Hepatitis Screening. American Journal of Public Health 100:S1, S118-S124
CrossRef25
Chi-Jen Chu, Shou-Dong Lee. (2010) Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?. Journal of Gastroenterology and Hepatology 25:2, 221-223
CrossRef26
T. Ohki, R. Tateishi, E. Goto, T. Sato, R. Masuzaki, J. Imamura, T. Goto, F. Kanai, N. Kato, S. Shiina, H. Yoshida, T. Kawabe, M. Omata. (2010) Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors. Journal of Viral Hepatitis 17:2, 91-97
CrossRef27
Li-Wei Chen, Rong-Nan Chien, Cho-Li Yen, Jia-Jang Chang, Ching-Jung Liu, Chih-Lang Lin. (2010) Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection. Journal of Gastroenterology and Hepatology 25:2, 259-263
CrossRef28
M. J. SHALE, C. H. SEOW, C. S. COFFIN, G. G. KAPLAN, R. PANACCIONE, S. GHOSH. (2010) Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 31:1, 20-34
CrossRef29
Tansu Sav, Sebnem Gursoy, Edip Torun, Nadide Melike Sav, Aydin Unal, Oktay Oymak, Cengiz Utas. (2010) Occult HBV Infection in Continuous Ambulatory Peritoneal Dialysis and Hemodialysis Patients. Renal Failure 32:1, 74-77
CrossRef30
Simona Urbani, Francesco Fagnoni, Gabriele Missale, Massimo Franchini. (2010) The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clinical Chemistry and Laboratory Medicine 48:1, 23-29
CrossRef31
Jorge S. Motta, Francisco C. Mello, Barbara V. Lago, Renata M. Perez, Selma A. Gomes, Fatima F. Figueiredo. (2010) Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis. Journal of Gastroenterology and Hepatology 25:1, 101-106
CrossRef32
F. B. Hollinger, G. Sood. (2010) Occult hepatitis B virus infection: a covert operation. Journal of Viral Hepatitis 17:1, 1-15
CrossRef33
Ching-Feng Lin, Shiing-Jer Twu, Ping-Ho Chen, Jror-Serk Cheng, Jung-Der Wang. (2010) Prevalence and Determinants of Hepatitis B Antigenemia in 15 007 Inmates in Taiwan. Journal of Epidemiology 20:3, 231-236
CrossRef34
Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen. (2009) Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatology International 3:4, 517-525
CrossRef35
Kuan-Ta Wu, Kun-Ming Chung, I.-Che Feng, Ming-Jen Sheu, Hsing-Tao Kuo, Lok-Beng Koay, Chin-Yih Lin, Ling-Yu Tang, Sun-Lung Tsai. (2009) Acute hepatitis E virus infection in Taiwan 2002-2006 revisited: PCR shows frequent co-infection with multiple hepatitis viruses. Journal of Medical Virology 81:10, 1734-1742
CrossRef36
K. Ikeda, M. Kobayashi, T. Someya, S. Saitoh, T. Hosaka, N. Akuta, F. Suzuki, Y. Suzuki, Y. Arase, H. Kumada. (2009) Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. Journal of Viral Hepatitis 16:6, 437-443
CrossRef37
Akihiro Tamori, Takehiro Hayashi, Mayumi Shinzaki, Sawako Kobayashi, Shuji Iwai, Masaru Enomoto, Hiroyasu Morikawa, Hiroki Sakaguchi, Susumu Shiomi, Shigekazu Takemura, Shoji Kubo, Norifumi Kawada. (2009) Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. Journal of Medical Virology 81:6, 1009-1014
CrossRef38
Carla S Coffin, Norah A Terrault. (2009) Management of patients co-infected with HBV and HCV. Expert Review of Anti-infective Therapy 7:5, 549-558
CrossRef39
Assem El-Sherif, Mohamed Abou-Shady, Hany Abou-Zeid, Ahmed Elwassief, Ashraf Elbahrawy, Yoshihide Ueda, Tsutomu Chiba, Abdel-Moneim Hosney. (2009) Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. Journal of Gastroenterology 44:4, 359-364
CrossRef40
Zeinab N.A. Said, Manal H. El-Sayed, Iman A. El-Bishbishi, Daad F. El-Fouhil, Soad E. Abdel-Rheem, Maha Z. El-Abedin, Iman I. Salama. (2009) High prevalence of occult hepatitis B in hepatitis C-infected Egyptian children with haematological disorders and malignancies. Liver International 29:4, 518-524
CrossRef41
Gollapudi Tarun Kumar, Syed Naqui Kazim, Manoj Kumar, Syed Hissar, Ranjit Chauhan, Seemi Farhat Basir, Shiv Kumar Sarin. (2009) Hepatitis B virus genotypes and hepatitis B surface antigen mutations in family contacts of hepatitis B virus infected patients with occult hepatitis B virus infection. Journal of Gastroenterology and Hepatology 24:4, 588-598
CrossRef42
M. STEELE, A. COCHRANE, C. WAKEFIELD, A-M. STAIN, S. LING, V. BLANCHETTE, R. GOLD, L. FORD-JONES. (2009) Hepatitis A and B immunization for individuals with inherited bleeding disorders. Haemophilia 15:2, 437-447
CrossRef43
Pierluigi Toniutto, Rosalba Minisini, Carlo Fabris, Tullia De Feo, Francesca Marangoni, Michela Burlone, Claudio Avellini, Davide Bitetto, Ezio Fornasiere, Elisa Fumolo, Umberto Baccarani, Mario Pirisi. (2009) Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression. Clinical Transplantation 23:2, 184-190
CrossRef44
Chun–Jen Liu, Wan–Long Chuang, Chuan–Mo Lee, Ming–Lung Yu, Sheng–Nan Lu, Shun–Sheng Wu, Li–Ying Liao, Chi–Ling Chen, Hsing–Tao Kuo, You–Chen Chao, Shui–Yi Tung, Sien–Sing Yang, Jia–Horng Kao, Chen–Hua Liu, Wei–Wen Su, Chih–Lin Lin, Yung–Ming Jeng, Pei–Jer Chen, Ding–Shinn Chen. (2009) Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. Gastroenterology 136:2, 496-504.e3
CrossRef45
Davide Rossi, Lisa Sala, Rosalba Minisini, Carlo Fabris, Edmondo Falleti, Michaela Cerri, Michela Emma Burlone, Pierluigi Toniutto, Gianluca Gaidano, Mario Pirisi. (2009) Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 50:4, 604-611
CrossRef46
Ioannis S. Elefsiniotis, Christos Pavlidis, Elena Vezali, Theodoros Mariolis-Sapsakos, Sotirios Koutsounas, George Saroglou. (2009) Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly Viremic Chronic Hepatitis C Patients. Gastroenterology Research and Practice 2009, 1-5
CrossRef47
H. PATEL, E. J. HEATHCOTE. (2009) When to treat and the benefits of treating hepatitis C in patients with haemophilia. Haemophilia 15:1, 20-32
CrossRef48
Lionel Piroth, Fabrice Carrat, Sylvie Larrat, Isabelle Goderel, Benoit Martha, Christopher Payan, Françoise Lunel-Fabiani, Firouze Bani-Sadr, Christian Perronne, Patrice Cacoub, Stanislas Pol, Patrice Morand. (2008) Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV–HCV co-infected patients on HCV therapy. Journal of Hepatology 49:6, 892-898
CrossRef49
S. Domm, J. Cinatl, U. Mrowietz. (2008) The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature. British Journal of Dermatology 159:6, 1217-1228
CrossRef50
Anna Linda Zignego, Alessia Piluso, Carlo Giannini. (2008) HBV and HCV chronic infection: Autoimmune manifestations and lymphoproliferation. Autoimmunity Reviews 8:2, 107-111
CrossRef51
Mohammad Kazemi Arababadi, Gholamhossein Hassanshahi, Hassan Yousefi, Ebrahim Rezazadeh Zarandi, Mohammad Moradi, Mahdi Mahmoodi. (2008) No Detected Hepatitis B Virus-DNA in Thalassemic Patients Infected by Hepatitis C Virus in Kerman Province of Iran. Pakistan Journal of Biological Sciences 11:13, 1738-1741
CrossRef52
Giovanni Raimondo, Jean-Pierre Allain, Maurizia R. Brunetto, Marie-Annick Buendia, Ding-Shinn Chen, Massimo Colombo, Antonio Craxì, Francesco Donato, Carlo Ferrari, Giovanni B. Gaeta, Wolfram H. Gerlich, Massimo Levrero, Stephen Locarnini, Thomas Michalak, Mario U. Mondelli, Jean-Michel Pawlotsky, Teresa Pollicino, Daniele Prati, Massimo Puoti, Didier Samuel, Daniel Shouval, Antonina Smedile, Giovanni Squadrito, Christian Trépo, Erica Villa, Hans Will, Alessandro R. Zanetti, Fabien Zoulim. (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. Journal of Hepatology 49:4, 652-657
CrossRef53
Ali Shorbagi, Yusuf Bayraktar. (2008) Occult Hepatitis B is not Necessarily an Infection. Journal of Clinical Gastroenterology 42:9, 1064-1065
CrossRef54
Claudio Velati, Luisa Romanò, Laura Fomiatti, Lorella Baruffi, Alessandro Remo Zanetti, . (2008) Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 48:10, 2205-2213
CrossRef55
F.-C. Tseng, B. R. Edlin, M. Zhang, A. Kral, M. P. Busch, B. A. Ortiz-Conde, T. M. Welzel, T. R. O’Brien. (2008) The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. Journal of Viral Hepatitis 15:9, 690-698
CrossRef56
Vincent Lo Re, Benjamin Wertheimer, A. Russell Localio, Jay R. Kostman, Janel Dockter, Jeffrey M. Linnen, Cristina Giachetti, Zachariah Dorey-Stein, Ian Frank, Brian L. Strom, Robert Gross. (2008) Incidence of transaminitis among HIV-infected patients with occult hepatitis B. Journal of Clinical Virology 43:1, 32-36
CrossRef57
Michael C Kew, Robert Welschinger, Raquel Viana. (2008) Occult hepatitis B virus infection in Southern African blacks with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 23:9, 1426-1430
CrossRef58
K.B. Gibney, J. Torresi, C. Lemoh, B.A. Biggs. (2008) Isolated core antibody hepatitis B in sub-Saharan African immigrants. Journal of Medical Virology 80:9, 1565-1569
CrossRef59
Sagnelli Evangelista, Imparato Michele, Coppola Nicola, Pisapia Raffaella, Sagnelli Caterina, Messina Vincenzo, Piai Guido, Stanzione Maria, Bruno Marika, Moggio Giovanni, Caprio Nunzio, Pasquale Giuseppe, Del Vecchio Blanco Camillo. (2008) Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: A multicenter study. Journal of Medical Virology 80:9, 1547-1553
CrossRef60
Gail V Matthews, Gregory J Dore. (2008) HIV and hepatitis C coinfection. Journal of Gastroenterology and Hepatology 23:7pt1, 1000-1008
CrossRef61
Yukiko Miura, Akitaka Shibuya, Shigeru Adachi, Atsuko Takeuchi, Takeshi Tsuchihashi, Takahide Nakazawa, Katsunori Saigenji. (2008) Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatology Research 38:6, 546-556
CrossRef62
Katsuaki Tanaka. (2008) Does occult hepatitis B virus infection cause hepatocellular carcinoma in patients with chronic liver disease related to hepatitis C virus?. Hepatology Research 38:6, 543-545
CrossRef63
Maria Pleguezuelo, Laura Marelli, Sergio Maimone, Pinelopi Manousou, Elias Xirouchakis, Andrew K. Burroughs. (2008) Does HCV antiviral therapy decrease the risk of hepatocellular carcinoma?. Current Hepatitis Reports 7:2, 72-80
CrossRef64
A. Mangia, F. Antonucci, M. Brunetto, M. Capobianchi, S. Fagiuoli, M. Guido, P. Farci, P. Lampertico, A. Marzano, G. Niro, G. Pisani, D. Prati, M. Puoti, G. Raimondo, T. Santantonio, A. Smedile, F. Lauria. (2008) The use of molecular assays in the management of viral hepatitis. Digestive and Liver Disease 40:6, 395-404
CrossRef65
Ming-Huang Chen, Liang-Tsai Hsiao, Tzeon-Jye Chiou, Jin-Hwang Liu, Jyh-Pyng Gau, Hao-Wei Teng, Wei-Shu Wang, Ta-Chung Chao, Chueh-chuan Yen, Po-Min Chen. (2008) High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma. Annals of Hematology 87:6, 475-480
CrossRef66
Sharif B. Missiha, Mario Ostrowski, E. Jenny Heathcote. (2008) Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors. Gastroenterology 134:6, 1699-1714
CrossRef67
Vicente Carreño*, Javier Bartolomé, Inmaculada Castillo, Juan Antonio Quiroga. (2008) Occult hepatitis B virus and hepatitis C virus infections. Reviews in Medical Virology 18:3, 139-157
CrossRef68
Giovanni Raimondo, Giuseppe Navarra, Stefania Mondello, Lucy Costantino, Guido Colloredo, Eugenio Cucinotta, Gaetano Di Vita, Claudio Scisca, Giovanni Squadrito, Teresa Pollicino. (2008) Occult hepatitis B virus in liver tissue of individuals without hepatic disease. Journal of Hepatology 48:5, 743-746
CrossRef69
Alessandro Zerbini, Massimo Pilli, Carolina Boni, Paola Fisicaro, Amalia Penna, Paola Di Vincenzo, Tiziana Giuberti, Alessandra Orlandini, Giuseppina Raffa, Teresa Pollicino, Giovanni Raimondo, Carlo Ferrari, Gabriele Missale. (2008) The Characteristics of the Cell-Mediated Immune Response Identify Different Profiles of Occult Hepatitis B Virus Infection. Gastroenterology 134:5, 1470-1481
CrossRef70
Gavin Bart, Paola Piccolo, Linqi Zhang, Ira Jacobson, Robert A. Schaefer, Mary Jeanne Kreek. (2008) Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. Addiction 103:4, 681-686
CrossRef71
Kirti Shetty, Munira Hussain, Lei Nei, K. Rajender Reddy, Anna S.F. Lok. (2008) Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transplantation 14:4, 534-540
CrossRef72
Chi-Jen Chu, Shou-Dong Lee. (2008) Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment. Journal of Gastroenterology and Hepatology 23:4, 512-520
CrossRef73
Montserrat Laguno, Maria Larrousse, José Luis Blanco, Agathe Leon, Ana Milinkovic, Maria Martínez-Rebozler, Montserrat Loncá, Esteban Martinez, Jose Maria Sanchez-Tapias, Elisa de Lazzari, José Maria Gatell, Josep Costa, Josep Mallolas. (2008) Prevalence and Clinical Relevance of Occult Hepatitis B in the Fibrosis Progression and Antiviral Response to INF Therapy in HIV–HCV-Coinfected Patients. AIDS Research and Human Retroviruses 24:4, 547-553
CrossRef74
Francesco Vitale, Fabio Tramuto, Ambrogio Orlando, Giovanni Vizzini, Valentina Meli, Giuseppe Cerame, Walter Mazzucco, Roberto Virdone, Ugo Palazzo, Maria Rosaria Villafrate, Alessandro Tagger, Nino Romano. (2008) Can the serological status of “anti-HBc alone” be considered a sentinel marker for detection of “occult” HBV infection?. Journal of Medical Virology 80:4, 577-582
CrossRef75
S. Ramia, A. I. Sharara, M. El-Zaatari, F. Ramlawi, Z. Mahfoud. (2008) Occult hepatitis B virus infection in Lebanese patients with chronic hepatitis C liver disease. European Journal of Clinical Microbiology & Infectious Diseases 27:3, 217-221
CrossRef76
Hidenori Toyoda, Takashi Kumada, Yuji Kaneoka, Yoshiki Murakami. (2008) Impact of hepatitis B virus (HBV) X gene integration in liver tissue on hepatocellular carcinoma development in serologically HBV-negative chronic hepatitis C patients. Journal of Hepatology 48:1, 43-50
CrossRef77
Jun Hanaoka, Mitsuo Shimada, Toru Ikegami, Satoru Imura, Yuji Morine, Hirofumi Kanemura, Yusuke Arakawa. (2008) A case of surgical treatment for hepatocellular carcinoma that developed in a chronic hepatitis C patient who had shown sustained virological response to interferon 11 years before. Kanzo 49:6, 248-254
CrossRef78
Mikako Obika, Toshiyuki Shinji, Shin-ichi Fujioka, Ryo Terada, Hiromasa Ryuko, Aye Aye Lwin, Hidenori Shiraha, Norio Koide. (2008) Hepatitis B Virus DNA in Liver Tissue and Risk for Hepatocarcinogenesis in Patients with Hepatitis C Virus-Related Chronic Liver Disease. Intervirology 51:1, 59-68
CrossRef79
W.-H. Sheng, J.-H. Kao, P.-J. Chen, L.-M. Huang, S.-Y. Chang, H.-Y. Sun, C.-C. Hung, M.-Y. Chen, S.-C. Chang. (2007) Evolution of Hepatitis B Serological Markers in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases 45:9, 1221-1229
CrossRef80
Nurit Tweezer-Zaks, Anat Doron-Libner, Perez Weiss, Shomron Ben-Horin, Iris Barshack, Merav Lidar, Avi Livneh. (2007) Familial Mediterranean Fever and Cryptogenic Cirrhosis. Medicine 86:6, 355-362
CrossRef81
Gaia Nebbia, Ana Garcia-Diaz, Ursula Ayliffe, Colette Smith, Samir Dervisevic, Margaret Johnson, Richard Gilson, Richard Tedder, Anna Maria Geretti. (2007) Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. Journal of Medical Virology 79:10, 1464-1471
CrossRef82
Giuseppina Raffa, Sergio Maimone, Antonietta Cargnel, Teresa Santantonio, Giorgio Antonucci, Marco Massari, Monica Schiavini, Gaia Caccamo, Teresa Pollicino, Giovanni Raimondo. (2007) Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 21:16, 2171-2175
CrossRef83
Tomasz I Michalak, Tram NQ Pham, Patricia M Mulrooney-Cousins. (2007) Molecular diagnosis of occult HCV and HBV infections. Future Virology 2:5, 451-465
CrossRef84
George N. Ioannou, Meaghan F. Splan, Noel S. Weiss, George B. McDonald, Laura Beretta, Sum P. Lee. (2007) Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology 5:8, 938-945.e4
CrossRef85
S. Mrani, I. Chemin, K. Menouar, O. Guillaud, P. Pradat, G. Borghi, M.A. Trabaud, P. Chevallier, M. Chevallier, F. Zoulim, C. Trépo. (2007) Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. Journal of Medical Virology 79:8, 1075-1081
CrossRef86
MK Osborn, JL Guest, D Rimland. (2007) Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease. HIV Medicine 8:5, 271-279
CrossRef87
M. Rodríguez-Torres, J. Gonzalez-Garcia, N. Bräu, R. Solá, S. Moreno, J. Rockstroh, F. Smaill, M.C. Mendes-Correa, J. DePamphilis, F.J. Torriani, . (2007) Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: Clinically relevant or a diagnostic problem?. Journal of Medical Virology 79:6, 694-700
CrossRef88
Winnie Yeo, Frankie K. F. Mo, Stephen L. Chan, Nancy W. Y. Leung, Pun Hui, Wai-Yip Lam, Tony S. K. Mok, Kowk C. Lam, Wing M. Ho, Jane Koh, Julian W. Tang, Anthony T. Chan, Paul K. S. Chan. (2007) Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 45:6, 1382-1389
CrossRef89
M. Masarone, V. La Mura, S. Bruno, G. B. Gaeta, R. Vecchione, F. Carrino, F. Moschella, R. Torella, M. Persico. (2007) Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease. Journal of Viral Hepatitis 0:0, 070501060544001-???
CrossRef90
Tatjana Tallo, Helene Norder, Valentina Tefanova, Tõnu Krispin, Jelena Schmidt, Madis Ilmoja, Karen Orgulas, Kaije Pruunsild, Ludmilla Priimägi, Lars O. Magnius. (2007) Genetic characterization of hepatitis C virus strains in Estonia: Fluctuations in the predominating subtype with time. Journal of Medical Virology 79:4, 374-382
CrossRef91
Erika Santos Corraliza, Aurelio Fuertes Martín. (2007) Aspectos actuales de la patogenia, diagnóstico y tratamiento de la hepatitis B. Medicina Clínica 128:15, 579-583
CrossRef92
Vincent Lo Re, Ian Frank, Robert Gross, Janel Dockter, Jeffrey M Linnen, Cristina Giachetti, Pablo Tebas, John Stern, Marie Synnestvedt, A Russell Localio, Jay R Kostman, Brian L Strom. (2007) Prevalence, Risk Factors, and Outcomes for Occult Hepatitis B Virus Infection Among HIV-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:3, 315-320
CrossRef93
Inmaculada Castillo, Elena Rodríguez-Iñigo, Juan Manuel López-Alcorocho, Javier Bartolomé, Margarita Pardo, Vicente Carreño. (2007) Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection. Journal of Medical Virology 79:3, 236-241
CrossRef94
Seong Man Kim, Ki Sung Lee, Chi Jun Park, Ja Young Lee, Kyung Ho Kim, Joon Yong Park, Jin Heon Lee, Hak Yang Kim, Jae Young Yoo, Myoung Kuk Jang. (2007) Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. Journal of Infection 54:2, 185-191
CrossRef95
Ying Huang, Jordan J. Feld, Ronda K. Sapp, Santosh Nanda, Jiing-Huey Lin, Lawrence M. Blatt, Michael W. Fried, Krishna Murthy, T. Jake Liang. (2007) Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C. Gastroenterology 132:2, 733-744
CrossRef96
Teresa Pollicino, Giuseppina Raffa, Lucy Costantino, Antonella Lisa, Cesare Campello, Giovanni Squadrito, Massimo Levrero, Giovanni Raimondo. (2007) Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 45:2, 277-285
CrossRef97
Giovanni Raimondo, Teresa Pollicino, Irene Cacciola, Giovanni Squadrito. (2007) Occult hepatitis B virus infection. Journal of Hepatology 46:1, 160-170
CrossRef98
T. Umemura, H. Muto, E. Tanaka, A. Matsumoto, T. Ichijo, K. Yoshizawa, T. Akamatsu, K. Kiyosawa, . (2007) Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C. Journal of Viral Hepatitis 14:1, 48-54
CrossRef99
Rita Jakiche, Matthew E. Borrego, Dennis W. Raisch, Gireesh V. Gupchup, Manjunath A. Pai, Antoine Jakiche. (2007) The Cost-Effectiveness of Two Strategies for Vaccinating U.S. Veterans with Hepatitis C Virus Infection against Hepatitis A and Hepatitis B Viruses. The American Journal of the Medical Sciences 333:1, 26-34
CrossRef100
Catherine Chakvetadze, Firouzé Bani-Sadr, Catherine Le Pendeven, Franck Lamontagne, Jean Paul Vincensini, Gilles Pialoux. (2007) Reactivation of hepatitis B virus replication during peginterferon–ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated anti-hepatitis B core antibodies. AIDS 21:3, 393-394
CrossRef101
Lan Lin, Chris Verslype, Jos F. van Pelt, Marc van Ranst, Johan Fevery. (2006) Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses. European Journal of Gastroenterology & Hepatology 18:12, 1311-1319
CrossRef102
Vincenzo Mazzaferro, Raffaele Romito, Marcello Schiavo, Luigi Mariani, Tiziana Camerini, Sherrie Bhoori, Lorenzo Capussotti, Fulvio Calise, Riccardo Pellicci, Giulio Belli, Alessandro Tagger, Massimo Colombo, Ferruccio Bonino, Pietro Majno, Josep M. Llovet, . (2006) Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44:6, 1543-1554
CrossRef103
Mehmet Kanbay, Gurden Gur, Ali Akcay, Haldun Selcuk, Ugur Yilmaz, Hande Arslan, Sedat Boyacioglu, Fatma Nurhan Ozdemir. (2006) Is Hepatitis C Virus Positivity a Contributing Factor to Occult Hepatitis B Virus Infection in Hemodialysis Patients?. Digestive Diseases and Sciences 51:11, 1962-1966
CrossRef104
Gaston R. Picchio, Patricia C. Bare, Valeria I. Descalzi, Maria V. Bussy, Sonia M. Soria, Maria P. Raffa, Nancy E. Mazzencio, Silvina Etchehun, Juan A. Camera, Donald E. Mosier, Federico G. Villamil. (2006) High prevalence of infection with a single hepatitis C virus genotype in a small rural community of Argentina. Liver International 26:6, 660-665
CrossRef105
Chuan-Mo Lee, Sheng-Nan Lu, Chao-Hung Hung, Wei-Chih Tung, Jing-Houng Wang, Hung-Da Tung, Chien-Hung Chen, Tsung-Hui Hu, Chi-Sin Changchien, Wei-Jen Chen. (2006) Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Transactions of the Royal Society of Tropical Medicine and Hygiene 100:8, 767-774
CrossRef106
C.-K. Hui, E. Lau, A. Monto, M. Kim, J. M. Luk, R. T. P. Poon, N. Leung, C.-M. Lo, S.-T. Fan, G. K. K. Lau, T. L. Wright. (2006) Natural History of Patients with Recurrent Chronic Hepatitis C Virus and Occult Hepatitis B Co-Infection after Liver Transplantation.. American Journal of Transplantation 6:7, 1600-1608
CrossRef107
F Donato, U Gelatti, R M Limina, G Fattovich. (2006) Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 25:27, 3756-3770
CrossRef108
M Levrero. (2006) Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25:27, 3834-3847
CrossRef109
Pietro Filippini, Nicola Coppola, Raffaella Pisapia, Carlo Scolastico, Cecilia Marrocco, Antonella Zaccariello, Cesare Nacca, Caterina Sagnelli, Giulio De Stefano, Teresa Ferraro, Carlo De Stefano, Evangelista Sagnelli. (2006) Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 20:9, 1253-1260
CrossRef110
Alessandro R. Zanetti, Luisa Romanò, Alessandra Zappá, Claudio Velati. (2006) Changing patterns of hepatitis B infection in Italy and NAT testing for improving the safety of blood supply. Journal of Clinical Virology 36, S51-S55
CrossRef111
Giovanni Squadrito, Teresa Pollicino, Irene Cacciola, Gaia Caccamo, Daniela Villari, Tiziana La Masa, Tea Restuccia, Eugenio Cucinotta, Claudio Scisca, Domenico Magazzu, Giovanni Raimondo. (2006) Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 106:6, 1326-1330
CrossRef112
Anurag Maheshwari, Paul J. Thuluvath. (2006) Cryptogenic Cirrhosis and NAFLD: Are They Related?. The American Journal of Gastroenterology 101:3, 664-668
CrossRef113
Jordan J. Feld, T. Jake Liang. (2006) Hepatitis C — identifying patients with progressive liver injury. Hepatology 43:S1, S194-S206
CrossRef114
James S. Park, Neeraj Saraf, Douglas T. Dieterich. (2006) HBV plus HCV, HCV plus HIV, HBV plus HIV. Current Gastroenterology Reports 8:1, 67-74
CrossRef115
Chee-Kin Hui, Eva Lau, Helen Wu, Alexander Monto, Michael Kim, John M Luk, George KK Lau, Teresa Lyn Wright. (2006) Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. Journal of Clinical Virology 35:2, 185-192
CrossRef116
I. Chemin, C. Trépo. (2005) Clinical impact of occult HBV infections. Journal of Clinical Virology 34, S15-S21
CrossRef117
K. Pogány, H.L. Zaaijer, J.M. Prins, F.W. Wit, J.M.A. Lange, M.G.H.M. Beld. (2005) Occult Hepatitis B Virus Infection before and 1 Year after Start of HAART in HIV Type 1-Positive Patients. AIDS Research and Human Retroviruses 21:11, 922-926
CrossRef118
Nanda Kerkar. (2005) Hepatitis B in children: Complexities in management. Pediatric Transplantation 9:5, 685-691
CrossRef119
A. A. Wagner, V. Loustaud-Ratti, I. Chemin, P. Weinbreck, F. Denis, S. Alain. (2005) Double hepatitis B virus infection in a patient with HIV/hepatitis C virus coinfection and ‘anti-HBc alone’ as serological pattern. European Journal of Clinical Microbiology & Infectious Diseases 24:9, 623-627
CrossRef120
J. J. Goedert, . (2005) Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001-2003. Haemophilia 11:5, 516-528
CrossRef121
Akihiro Tamori, Shuhei Nishiguchi, Susumu Shiomi, Takehiro Hayashi, Sawako Kobayashi, Daiki Habu, Tadashi Takeda, Shuichi Seki, Kazuhiro Hirohashi, Hiromu Tanaka, Shoji Kubo. (2005) Hepatitis B Virus DNA Integration in Hepatocellular Carcinoma After Interferon-Induced Disappearance of Hepatitis C Virus. The American Journal of Gastroenterology 100:8, 1748-1753
CrossRef122
Meike Hass, Charles Hannoun, Tatyana Kalinina, Gunhild Sommer, Christoph Manegold, Stephan Günther. (2005) Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology 42:1, 93-103
CrossRef123
C.M.D. Silva, C. Costi, C. Costa, C. Michelon, R. Oravec, A.B. Ramos, C. Niel, M.L. Rossetti. (2005) Low rate of occult hepatitis B virus infection among anti-HBc positive blood donors living in a low prevalence region in Brazil. Journal of Infection 51:1, 24-29
CrossRef124
HIRONORI TANAKA, YOSHIAKI IWASAKI, KAZUHIRO NOUSO, YOSHIYUKI KOBAYASHI, SHIN-ICHIRO NAKAMURA, EIJI MATSUMOTO, NOBUYUKI TOSHIKUNI, TOSHIHIKO KANEYOSHI, TOSHIYA OHSAWA, KOUICHI TAKAGUCHI, KOZO FUJIO, TOMONORI SENOH, TOHRU OHNISHI, KOHSAKU SAKAGUCHI, YASUSHI SHIRATORI. (2005) Possible contribution of prior hepatitis B virus infection to the development of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 20:6, 850-856
CrossRef125
A.A. Peres, E.A. Dias, M. Chesky, M.R. Alvares-da-Silva, L.F. Jobim, L.F. Goncalves, R.C. Manfro. (2005) Occult hepatitis B in renal transplant patients. Transplant Infectious Disease 7:2, 51-56
CrossRef126
E. Khattab, I. Chemin, I. Vuillermoz, C. Vieux, S Mrani, O Guillaud, C. Trepo, F. Zoulim. (2005) Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. Journal of Clinical Virology 33:2, 150-157
CrossRef127
James S. Park, Neeraj Saraf, Douglas T. Dieterich. (2005) Antiviral therapy in the HCV-coinfected patient with HIV and/or HBV. Current Hepatitis Reports 4:2, 68-74
CrossRef128
S. Momosaki, Y. Nakashima, M. Kojiro, E. Tabor. (2005) HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma. Journal of Viral Hepatitis 12:3, 325-329
CrossRef129
HAJIME TOKITA, HIDEO FUKUI, AKIHISA TANAKA, HIROSHI KAMITSUKASA, MICHIYASU YAGURA, HIDEHARU HARADA, HIROAKI OKAMOTO. (2005) Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. Journal of Gastroenterology and Hepatology 20:5, 752-758
CrossRef130
Izumi Hasegawa, Etsuro Orito, Yasuhito Tanaka, Noboru Hirashima, Kenji Sakakibara, Mayumi Sakurai, Seiji Suzuki, Fuminaka Sugauchi, Tomoyoshi Ohno, Ryuzo Ueda, Masashi Mizokami. (2005) Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver International 25:2, 247-253
CrossRef131
Giovanni Raimondo, Teresa Pollicino, Giovanni Squadrito. (2005) What is the clinical impact of occult hepatitis B virus infection?. The Lancet 365:9460, 638-640
CrossRef132
Javier Colomina-Rodríguez, David González-García, Antonio Burgos-Teruel, Natalia Fernández-Lorenz, Antonio Guerrero-Espejo. (2005) Significado de la reactividad aislada anti-HBc como único marcador de infección de la hepatitis B. Enfermedades Infecciosas y Microbiología Clínica 23:2, 80-85
CrossRef133
Evangelista Sagnelli, Giuseppe Pasquale, Nicola Coppola, Cecilia Marrocco, Ferdinando Scarano, Michele Imparato, Caterina Sagnelli, Carlo Scolastico, Felice Piccinino. (2005) Liver histology in patients with HBsAg negative anti-HBc and anti-HCV positive chronic hepatitis. Journal of Medical Virology 75:2, 222-226
CrossRef134
Jordan J. Feld, T. Jake Liang. (2005) HCV persistence: Cure is still a four letter word. Hepatology 41:1, 23-25
CrossRef135
T JACOB JOHN, GRAHAM COOKSLEY. (2005) Hepatitis B vaccine boosters: Is there a clinical need in high endemicity populations?. Journal of Gastroenterology and Hepatology 20:1, 5-10
CrossRef136
Bernard Weber, Annemarie Berger. (2005) Molecular detection of hepatitis B virus: recent developments. Molekularer Nachweis des Hepatitis B-Virus: Aktueller Entwicklungsstand. LaboratoriumsMedizin 29:1, 33-43
CrossRef137
ANNA SF LOK. (2004) Occult hepatitis B virus infection: diagnosis, implications and management?. Journal of Gastroenterology and Hepatology 19:s7, S114-S117
CrossRef138
KEI FUJIWARA, YASUHITO TANAKA, ETSURO ORITO, TOMOYOSHI OHNO, TAKANOBU KATO, FUMINAKA SUGAUCHI, SEIJI SUZUKI, YUKO HATTORI, MAYUMI SAKURAI, IZUMI HASEGAWA, TAKASHI OZASA, FUTOSHI KANIE, HIDEYUKI KANO, RYUZO UEDA, MASASHI MIZOKAMI. (2004) Lack of association between occult hepatitis B virus DNA viral load and aminotransferase levels in patients with hepatitis C virus-related chronic liver disease. Journal of Gastroenterology and Hepatology 19:12, 1343-1347
CrossRef139
Phyllis C. Tien, Andrea Kovacs, Peter Bacchetti, Audrey L. French, Michael Augenbraun, Stephen R. Cole, Nancy Hessol, Jessica Justman. (2004) Association between Syphilis, Antibodies to Herpes Simplex Virus Type 2, and Recreational Drug Use and Hepatitis B Virus Infection in the Women’s Interagency HIV Study. Clinical Infectious Diseases 39:9, 1363-1370
CrossRef140
Natsuko Tsuda, Nobukazu Yuki, Kiyoshi Mochizuki, Takayuki Nagaoka, Masatoshi Yamashiro, Masao Omura, Kazumasa Hikiji, Michio Kato. (2004) Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. Journal of Medical Virology 74:3, 406-413
CrossRef141
M. G. Rumi, F. De Filippi, E. Santagostino, M. Colombo. (2004) Hepatitis C in haemophilia: lights and shadows. Haemophilia 10:s4, 211-215
CrossRef142
J. J. Goedert, D. L. Brown, K. Hoots, K. E. Sherman. (2004) Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia. Haemophilia 10:s4, 205-210
CrossRef143
T. E. S. Delahooke. (2004) What is the nature of the problem?. Journal of Viral Hepatitis 11:s1, 5-11
CrossRef144
Azucena Rodr??guez Guardado, Mercedes Rodr??guez P??rez, Jose A. Maradona, Ana Mart??nez, Victor Asensi, Jose A. Cart??n. (2004) Isolated Presence of Antibody to Hepatitis B Core Antigen in Patients Coinfected With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 36:4, 988-989
CrossRef145
Norah J. Shire, Susan D. Rouster, Natasa Rajicic, Kenneth E. Sherman. (2004) Occult Hepatitis B in HIV-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 36:3, 869-875
CrossRef146
S. P. Georgiadou, K. Zachou, E. Rigopoulou, C. Liaskos, P. Mina, F. Gerovasilis, E. Makri, G. N. Dalekos. (2004) Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases*. Journal of Viral Hepatitis 11:4, 358-365
CrossRef147
Hidenori Toyoda, Kazuhiko Hayashi, Yoshiki Murakami, Takashi Honda, Yoshiaki Katano, Isao Nakano, Hidemi Goto, Takashi Kumada, Junki Takamatsu. (2004) Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. Journal of Medical Virology 73:2, 195-199
CrossRef148
Luisa Fernanda Mariscal, Elena Rodr
guez-I
CrossRef149
G. Reiss, E. B. Keeffe. (2004) Hepatitis vaccination in patients with chronic liver disease. Alimentary Pharmacology and Therapeutics 19:7, 715-727
CrossRef150
Oluwatoyin M. Adeyemi, Donald Jensen, Bashir Attar, Rony Ghaoui, Maureen Gallagher, Deborah Wolen, Scott J. Cotler. (2004) Hepatitis C Treatment Eligibility in an Urban Population with and without HIV Coinfection. AIDS Patient Care and STDs 18:4, 239-245
CrossRef151
Alexander C. Haushofer, René Hauer, Harald Brunner, Ursula Köller, Doris Trubert-Exinger, Walter-Michael Halbmayer, Christoph Koidl, Harald H. Kessler. (2004) No evidence of hepatitis B virus activity in patients with anti-HBc antibody positivity with or without anti-hepatitis C virus antibody positivity. Journal of Clinical Virology 29:4, 221-223
CrossRef152
Paolo Fabris, Dave Brown, Giulia Tositti, Loredana Bozzola, Maria Teresa Giordani, Pierantonio Bevilacqua, Fausto de Lalla, George J.M. Webster, Geoffrey Dusheiko. (2004) Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. Journal of Clinical Virology 29:3, 160-166
CrossRef153
Valeria Ghisetti, Alfredo Marzano, Fausto Zamboni, Anna Barbui, Alessandro Franchello, Silvia Gaia, Giovanna Marchiaro, Mauro Salizzoni, Mario Rizzetto. (2004) Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: Clinical significance. Liver Transplantation 10:3, 356-362
CrossRef154
Yoshiki Murakami, Masahito Minami, Yukiko Daimon, Takeshi Okanoue. (2004) Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. Journal of Medical Virology 72:2, 203-214
CrossRef155
Takeshi Tanaka, Kazuaki Inoue, Yukiko Hayashi, Aki Abe, Kyoko Tsukiyama-Kohara, Hideko Nuriya, Yoshikazu Aoki, Ryuji Kawaguchi, Kiichi Kubota, Makoto Yoshiba, Morio Koike, Satoshi Tanaka, Michinori Kohara. (2004) Virological significance of low-level hepatitis B virus infection in patients with hepatitis C virus associated liver disease. Journal of Medical Virology 72:2, 223-229
CrossRef156
J.-P. Allain. (2004) Occult hepatitis B virus infection: implications in transfusion. Vox Sanguinis 86:2, 83-91
CrossRef157
V. Soriano, J. M. Miro, J. Garcia-Samaniego, J. Torre-Cisneros, M. Nunez, J. del Romero, L. Martin-Carbonero, J. Castilla, J. A. Iribarren, C. Quereda, M. Santin, J. Gonzalez, J. R. Arribas, I. Santos, J. Hernandez-Quero, E. Ortega, V. Asensi, M. A. del Pozo, J. Berenguer, C. Tural, B. Clotet, M. Leal, J. Mallolas, J. M. Sanchez-Tapias, S. Moreno, J. M. Gatell, M. J. Tellez, R. Rubio, E. Ledesma, P. Domingo, P. Barreiro, J. Pedreira, M. Romero, J. Gonzalez-Lahoz, E. Lissen. (2004) Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. Journal of Viral Hepatitis 11:1, 2-17
CrossRef158
Christian Drosten, Thomas Nippraschk, Christoph Manegold, Helga Meisel, Veronika Brixner, W.Kurt Roth, Anani Apedjinou, Stephan Günther. (2004) Prevalence of hepatitis B virus DNA in anti-HBc-positive/HBsAg-negative sera correlates with HCV but not HIV serostatus. Journal of Clinical Virology 29:1, 59-68
CrossRef159
Teresa Pollicino, Giovanni Squadrito, Giovanni Cerenzia, Irene Cacciola, Giuseppina Raffa, Antonio Craxı̀, Fabio Farinati, Gabriele Missale, Antonina Smedile, Claudio Tiribelli, Erica Villa, Giovanni Raimondo. (2004) Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126:1, 102-110
CrossRef160
Jorge A. Marrero, Anna S.F. Lok. (2004) Occult hepatitis B virus infection in patients with hepatocellular carcinoma: innocent bystander, cofactor, or culprit?. Gastroenterology 126:1, 347-350
CrossRef161
Michael Torbenson, Rajesh Kannangai, Jacquie Astemborski, Steffanie A. Strathdee, David Vlahov, David L. Thomas. (2004) High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 39:1, 51-57
CrossRef162
Madhavi Chandra, Mohammad Nanne Khaja, Mohammad Mehaboob Hussain, Chetan Datta Poduri, Nafeesa Farees, Mohammad Aejaz Habeeb, Srinivasan Krishnan, Guntaka Venkata Ramareddy, Chittoor Mohammad Habibullah. (2004) Prevalence of Hepatitis B and Hepatitis CViral Infections in Indian Patients with Chronic Renal Failure. Intervirology 47:6, 374-376
CrossRef163
Akihiro Tamori, Shuhei Nishiguchi, Shoji Kubo, Takashi Narimatsu, Daiki Habu, Tadashi Takeda, Kazuhiro Hirohashi, Susumu Shiomi. (2003) HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. Journal of Medical Virology 71:4, 492-498
CrossRef164
Massimo Colombo. (2003) Hepatitis C infection and hepatocellular carcinoma. Current Hepatitis Reports 2:4, 166-172
CrossRef165
Rajesh T. Gandhi, Alysse Wurcel, Barbara McGovern, Hang Lee, Janet Shopis, Colleen P. Corcoran, Sarah Toner, Christina Giachetti, Janel Dockter, Paul E. Sax, Chinweike Ukomadu. (2003) Low Prevalence of Ongoing Hepatitis B Viremia in HIV-Positive Individuals with Isolated Antibody to Hepatitis B Core Antigen. JAIDS Journal of Acquired Immune Deficiency Syndromes 34:4, 439-441
CrossRef166
JIUN-GUEY LIN, TAKASHI GOTO, KUNIO NAKANE, KOUICHI MIURA, KEN-ICHIRO MIKAMI, SHIGETOSHI OHSHIMA, KAZUO YONEYAMA, SUMIO WATANABE. (2003) Clinical significance of SEN-virus on interferon response in chronic hepatitis C patients. Journal of Gastroenterology and Hepatology 18:10, 1144-1149
CrossRef167
Raymundo Paraná, Liana Codes, Zilton Andrade, Luiz A.R. de Freitas, Rogério Santos-Jesus, Mitermayer Reis, Helma Cotrim, Simone Cunha, Christian Trepo. (2003) Clinical, histologic and serologic evaluation of patients with acute non-A-E hepatitis in north-eastern Brazil: is it an infectious disease?. International Journal of Infectious Diseases 7:3, 222-230
CrossRef168
Elena Rodr
CrossRef169
Fadel Alhababi, Talal A. Sallam, C.Y.William Tong. (2003) The significance of ‘anti-HBc only’ in the clinical virology laboratory. Journal of Clinical Virology 27:2, 162-169
CrossRef170
R. T. Gandhi, A. Wurcel, H. Lee, B. McGovern, M. Boczanowski, R. Gerwin, C. P. Corcoran, Z. Szczepiorkowski, S. Toner, D. E. Cohen, P. E. Sax, C. Ukomadu. (2003) Isolated Antibody to Hepatitis B Core Antigen in Human Immunodeficiency Virus Type-1--Infected Individuals. Clinical Infectious Diseases 36:12, 1602-1605
CrossRef171
Chun-Jen Liu, Pei-Jer Chen, Wen-Yi Shau, Jia-Horng Kao, Ming-Yang Lai, Ding-Shinn Chen. (2003) Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. Liver International 23:3, 148-155
CrossRef172
P. J. Lum, K. C. Ochoa, J. A. Hahn, K. Page Shafer, J. L. Evans, A. R. Moss. (2003) Hepatitis B Virus Immunization Among Young Injection Drug Users in San Francisco, Calif: The UFO Study. American Journal of Public Health 93:6, 919-923
CrossRef173
C.C. Hsia, C.H. Scudamore, A.M. Di Bisceglie, E. Tabor. (2003) Molecular and serological aspects of HBsAg-negative hepatitis B virus infections in North America. Journal of Medical Virology 70:1, 20-26
CrossRef174
Akihiro Tamori, Shuhei Nishiguchi, Shoji Kubo, Masaru Enomoto, Noritoshi Koh, Tadashi Takeda, Susumu Shiomi, Kazuhiro Hirohashi, Hiroaki Kinoshita, Shuzo Otani. (2003) Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. Journal of Medical Virology 69:4, 475-481
CrossRef175
Vladimir P. Chulanov, German A. Shipulin, Stephan Schaefer, Wolfram H. Gerlich. (2003) Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. Journal of Medical Virology 69:3, 313-323
CrossRef176
R. P. Myers, V. Thibault, T. Poynard. (2003) The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. Journal of Viral Hepatitis 10:2, 103-110
CrossRef177
Hideji Hanabusa. (2002) Efficacy of Induction Therapy with High‐Dose Interferon for Patients with Hemophilia and Human Immunodeficiency Virus–Hepatitis C Virus Coinfection. Clinical Infectious Diseases 35:12, 1527-1533
CrossRef178
Alexander C Haushofer, René Hauer, Harald Brunner, Ursula Köller, Doris Trubert-Exinger, Walter-Michael Halbmayer, Josef Haas, Harald H Kessler. (2002) Hepatitis B virus activity in patients with anti-hepatitis C virus antibody positivity and hepatitis B antigen positivity. Journal of Clinical Virology 25, 99-102
CrossRef179
Jia-Horng Kao, Pei-Jer Chen, Ming-Yang Lai, Ding-Shinn Chen. (2002) Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. Journal of Medical Virology 68:2, 216-220
CrossRef180
B. Weber. (2002) The Isolated Anti-HBc Reactivity: New Developments/Die Bedeutung des isoliert anti-HBc positiven Befundes: neue Aspekte. LaboratoriumsMedizin 26:9-10, 451-458
CrossRef181
Marina Núñez, Pilar Ríos, Mayte Pérez-Olmeda, Vincent Soriano. (2002) Lack of ‘occult’ hepatitis B virus infection in HIV-infected patients. AIDS 16:15, 2099-2101
CrossRef182
Jonathan Allen Cohn. (2002) HIV-1 infection in injection drug users. Infectious Disease Clinics of North America 16:3, 745-770
CrossRef183
L. S. Diamondstone, L. M. Aledort, J. J. Goedert, . (2002) Factors predictive of death among HIV-uninfected persons with haemophilia and other congenital coagulation disorders. Haemophilia 8:5, 660-667
CrossRef184
Michael Torbenson, David L Thomas. (2002) Occult hepatitis B. The Lancet Infectious Diseases 2:8, 479-486
CrossRef185
Hajime Tokita, Seiyou Murai, Hiroshi Kamitsukasa, Michiyasu Yagura, Hideharu Harada, Masaharu Takahashi, Hiroaki Okamoto. (2002) High TT virus load as an independent factor associated with the occurrence of hepatocellular carcinoma among patients with hepatitis C virus-related chronic liver disease. Journal of Medical Virology 67:4, 501-509
CrossRef186
M. Cabrerizo, J. Bartolome, V. Carreno. (2002) In vitro infection of human peripheral blood mononuclear cells by a defective hepatitis B virus with a deletion in the PreS1 region of the viral genome. Journal of Viral Hepatitis 9:4, 265-271
CrossRef187
Ke-Qin Hu. (2002) Occult hepatitis B virus infection and its clinical implications. Journal of Viral Hepatitis 9:4, 243-257
CrossRef188
Vincent Leroy, Marc Bourliere, Magali Durand, Armand Abergel, Albert Tran, Maryline Baud, Danielle Botta-Fridlund, André Gerolami, Denis Ouzan, Philippe Halfon, Jean-Pierre Zarski. (2002) The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case–control study. European Journal of Gastroenterology & Hepatology 14:5, 485-489
CrossRef189
Kathleen Iosue. (2002) Chronic Hepatitis C: Latest Treatment Options. The Nurse Practitioner 27:4, 32-33
CrossRef190
M. Comar, F. Ansaldi, L. Morandi, G. Dal Molin, P. M. Foschini, S. L. Crocè, S. Bonin, G. Stanta, C. Tiribelli, C. Campello. (2002) In situ polymerase chain reaction detection of transfusion-transmitted virus in liver biopsy. Journal of Viral Hepatitis 9:2, 123-127
CrossRef191
D. Prati, F. Mozzi. (2002) Response 19. Vox Sanguinis 82:2, 87-111
CrossRef192
R. Di Stefano, D. Ferraro, C. Bonura, G. Pizzolanti, O. Lo Iacono, V. Di Marco, A. Craxì. (2002) Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease?. Digestive and Liver Disease 34:1, 53-58
CrossRef193
Yun-Fan Liaw. (2002) Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Journal of Gastroenterology 37:S13, 65-68
CrossRef194
Evangelista Sagnelli, Nicola Coppola, Carlo Scolastico, Anna Rita Mogavero, Maria Stanzione, Pietro Filippini, Francesca Maria Felaco, Felice Piccinino. (2001) Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. Journal of Medical Virology 65:4, 681-687
CrossRef195
Javier Garcia-Samaniego, Manuel Rodriguez, Vicente Soriano. (2001) Response to Drs. Toyoda et al.. The American Journal of Gastroenterology 96:12, 3441-3442
CrossRef196
Milan Dodig, Anthony S. Tavill. (2001) Hepatitis C and Human Immunodeficiency Virus Coinfections. Journal of Clinical Gastroenterology 33:5, 367-374
CrossRef197
Luisa Benvegnù, Alfredo Alberti. (2001) Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. Antiviral Research 52:2, 199-207
CrossRef198
I Chemin, D Jeantet, A Kay, C Trépo. (2001) Role of silent hepatitis B virus in chronic hepatitis B surface antigen(−) liver disease. Antiviral Research 52:2, 117-123
CrossRef199
Lawrence Serfaty, Dominique Costagliola, Dominique Wendum, Odile Picard, Marie-Caroline Meyohas, Pierre-Marie Girard, Jacques Lebas, Catherine Delamare, Raoul Poupon, Chantal Housset. (2001) Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case–control study. AIDS 15:15, 2011-2016
CrossRef200
Ren Wei Chen, Heli Piiparinen, Mikko Sepp
CrossRef201
Shigenobu Kawai, Osamu Yokosuka, Fumio Imazeki, Yasushi Maru, Hiromitsu Saisho. (2001) State of HBV DNA in HBsAg-negative, anti-HCV-positive hepatocellular carcinoma: Existence of HBV DNA possibly as nonintegrated form with analysis by Alu-HBV DNA PCR and conventional HBV PCR. Journal of Medical Virology 64:4, 410-418
CrossRef202
Bernard Weber, Walter Melchior, Ralph Gehrke, Hans Wilhelm Doerr, Annemarie Berger, Holger Rabenau. (2001) Hepatitis B virus markers in anti-HBc only positive individuals. Journal of Medical Virology 64:3, 312-319
CrossRef203
M.L. Rodriguez-Mendez, A. Gonzalez-Quintela, A. Aguilera. (2001) Serum transaminase values in HIV-infected patients with previous HBV infection, with and without HCV antibodies. The American Journal of Gastroenterology 96:7, 2272-2273
CrossRef204
Evangelista Sagnelli, Nicola Coppola, Carlo Scolastico, Anna Rita Mogavero, Pietro Filippini, Felice Piccinino. (2001) CV genotype and ?silent? HBV coinfection: Two main risk factors for a more severe liver disease. Journal of Medical Virology 64:3, 350-355
CrossRef205
Firdous Siddiqui, Milton Mutchnick, Joseph Kinzie, Rene Peleman, Paul Naylor, Murray Ehrinpreis. (2001) Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. The American Journal of Gastroenterology 96:3, 858-863
CrossRef206
I. Bica, B. McGovern, R. Dhar, D. Stone, K. McGowan, R. Scheib, D. R. Snydman. (2001) Increasing Mortality Due to End-Stage Liver Disease in Patients with Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 32:3, 492-497
CrossRef207
Kiyomi Ishiga, Toshio Kawatani, Takeaki Suou, Fumihito Tajima, Hiromi Omura, Youko Idobe, Hironaka Kawasaki. (2001) Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. International Journal of Hematology 73:1, 115-118
CrossRef208
Shuhei Nishiguchi, Susumu Shiomi, Shinji Nakatani, Tadashi Takeda, Katsuhiko Fukuda, Akihiro Tamori, Daiki Habu, Takashi Tanaka. (2001) Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. The Lancet 357:9251, 196-197
CrossRef209
Nicola Maria, Alessandra Colantoni, Lois Friedlander, Gioacchino Leandro, Ramazan Idilman, James Harig, David H. Thiel. (2000) The impact of previous HBV infection on the course of chronic hepatitis C. The American Journal of Gastroenterology 95:12, 3529-3536
CrossRef210
G. Raimondo, C. Balsano, A. Craxì, F. Farinati, M. Levrero, M. Mondelli, T. Pollicino, G. Squadrito, C. Tiribelli. (2000) Occult hepatitis B virus infection. Digestive and Liver Disease 32:9, 822-826
CrossRef211
Prati, Zanella, Zanuso, Vianello, E. Della Torre, Mozzi, Carriero, Zahm, Donato, Colombo, Sirchia, . (2000) Sustained response to interferon-alpha2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C. Journal of Viral Hepatitis 7:5, 352-360
CrossRef212
Zeuzem. (2000) Treatment of chronic hepatitis C virus infection in patients with cirrhosis. Journal of Viral Hepatitis 7:5, 327-334
CrossRef213
Michael A. Poles, Douglas T. Dieterich. (2000) INFECTIONS OF THE LIVER IN HIV-INFECTED PATIENTS. Infectious Disease Clinics of North America 14:3, 741-759
CrossRef214
Hugo R. Rosen, Paul Martin. (2000) VIRAL HEPATITIS IN THE LIVER TRANSPLANT RECIPIENT. Infectious Disease Clinics of North America 14:3, 761-784
CrossRef215
Antonio Bertoletti, Mala K Maini. (2000) Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?. Current Opinion in Microbiology 3:4, 387-392
CrossRef216
Antonio Bertoletti, Mala K Maini. (2000) Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?. Current Opinion in Immunology 12:4, 403-408
CrossRef217
M. A. Poles, D. T. Dieterich, K. H. Mayer. (2000) Hepatitis C Virus/Human Immunodeficiency Virus Coinfection: Clinical Management Issues. Clinical Infectious Diseases 31:1, 154-161
CrossRef218
Yoshizumi Shintani, Hiroshi Yotsuyanagi, Kyoji Moriya, Hajime Fujie, Takeya Tsutsumi, Tadatoshi Takayama, Masatoshi Makuuchi, Satoshi Kimura, Kazuhiko Koike. (2000) The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C. Cancer 88:11, 2478-2486
CrossRef219
Deepak Amarapurkar. (2000) Natural history of hepatitis C virus infection. Journal of Gastroenterology and Hepatology 15:5 (Suppl.), E105-E110
CrossRef220
John T. Edwards, Graeme A. Macdonald. (2000) Hepatocellular carcinoma. Current Opinion in Gastroenterology 16:3, 275-281
CrossRef221
Jay H. Lefkowitch. (2000) Pathology of the liver. Current Opinion in Gastroenterology 16:3, 200-207
CrossRef222
Damien Mallat, Eugene Schiff. (2000) Viral hepatitis. Current Opinion in Gastroenterology 16:3, 255-261
CrossRef223
Massimo Colombo. (2000) Hepatocellular carcinoma in patients with HCV. Best Practice & Research Clinical Gastroenterology 14:2, 327-339
CrossRef224
Kenneth R. Hirsch, Teresa L. Wright. (2000) ?Silent killer? or benign disease? The dilemma of hepatitis C virus outcomes. Hepatology 31:2, 536-537
CrossRef225
Hiroyuki Marusawa, Shinji Uemoto, Makoto Hijikata, Yoshihide Ueda, Koichi Tanaka, Kunitada Shimotohno, Tsutomu Chiba. (2000) Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31:2, 488-495
CrossRef226
Irene Cacciola, Teresa Pollicino, Giovanni Squadrito, Giovanni Cerenzia, Daniela Villari, Roberto de Franchis, Teresa Santantonio, Santa Brancatelli, Giuseppe Colucci, Giovanni Raimondo. (2000) Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology 31:2, 507-512
CrossRef
